AUROBAC THERAPEUTICS is a biopharmaceutical company created in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to develop the next generation of precision medicines addressing the medical needs associated with the development of antimicrobial resistance and infectious diseases. 
The company is building a pipeline of drug candidates for hospitalized patients, associated with rapid diagnostics to identify pathogens and their resistance mechanisms. 
This 40 million euros-funded joint-venture plans to cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization

Biotechnology

Pharmaceutical

Therapeutics

AUROBAC THERAPEUTICS

AUROBAC THERAPEUTICS' headquarters in Lyon, France

Description

People (2)

Jobs (0)

Other offices